S
Snigdha Samarpita
Researcher at VIT University
Publications - 12
Citations - 147
Snigdha Samarpita is an academic researcher from VIT University. The author has contributed to research in topics: Arthritis & RANKL. The author has an hindex of 4, co-authored 8 publications receiving 59 citations.
Papers
More filters
Journal ArticleDOI
Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug.
TL;DR: Based on the drug repositioning concept, TAK-242, used for the treatment of TLR4-mediated inflammatory diseases, shows potential for cost-effective development as a remedy for rheumatoid arthritis or to control the progression of RA.
Journal ArticleDOI
Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway.
TL;DR: The results demonstrated that ferulic acid significantly attenuated RANKL induced osteoclast differentiation as evidenced from SEM and TRAP staining analysis, and evidence the anti‐stimulatory and anti‐resorptive role of ferulic Acid via the inhibition of RankL dependent NF‐&kgr;B signalling pathway.
Journal ArticleDOI
Interleukin 17 under hypoxia mimetic condition augments osteoclast mediated bone erosion and expression of HIF-1α and MMP-9.
TL;DR: IL-17 synergizes with CoCl2 induced hypoxic condition to augment osteoclast mediated bone erosion and synovial macrophages mediated RA pathogenesis.
Journal ArticleDOI
Cyanidin prevents the hyperproliferative potential of fibroblast-like synoviocytes and disease progression via targeting IL-17A cytokine signalling in rheumatoid arthritis.
TL;DR: This study provides the first evidence that cyanidin can be used as IL-17/17RA signalling targeting therapeutic drug for the treatment of RA and this need to be investigated in RA patients.
Journal ArticleDOI
PdCl 2 -catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor.
B. Thirupataiah,Guntipally Mounika,Gangireddy Sujeevan Reddy,Jetta Sandeep Kumar,Kazi Amirul Hossain,Raghavender Medishetti,Snigdha Samarpita,Mahaboobkhan Rasool,Jayesh Mudgal,Jessy Elizabeth Mathew,Gautham G. Shenoy,C. Mallikarjuna Rao,Kiranam Chatti,Kishore V. L. Parsa,Manojit Pal +14 more
TL;DR: The isocoumarin 3u emerged as a new, safe and moderately selective PDE4B inhibitor could be useful for inflammatory diseases possibly including COVID-19.